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Abstract: Rheumatoid arthritis (RA) is a systemic inflammatory disease in which chronic 
inflammation leads to joint destruction and extra-articular complications. Early and effective 
inhibition of inflammation is critical in order to prevent the progressive joint damage that 
occurs rapidly after onset of the disease. In the past, treatment for this purpose was limited 
to  conventional  disease-modifying  antirheumatic  drugs  (DMARDs),  which  were  often 
suboptimal. Within the last decade however, the development of biologic therapies, targeted 
against  cytokines  and  cells  involved  in  the  inflammatory  process,  has  revolutionized  the 
management of RA. Disease remission is now an achievable goal in newly diagnosed patients. 
Since the advent of the first tumor necrosis factor-α inhibitor in 1999, other biologics have 
proved necessary as individuals respond to varying degrees with different therapies. Several 
are now available for the treatment of patients with RA that remains active despite DMARD 
treatment. This article reviews the evidence, over the last decade, of the efficacy and safety 
of biologic therapies used in this context, and the recent clinical data supporting the use of 
biologic therapy earlier in the disease process as first-line therapy.
Keywords: rheumatoid arthritis, biologic therapy, tumor necrosis factor, abatacept, rituximab, 
tocilizumab, safety
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting 1% of adult 
  Western populations, and is the largest cause of treatable disability in the Western 
World.1 It is associated with considerable pain, stiffness, and swelling of joints. If 
not adequately controlled, it results in joint destruction, deformity, and disability. 
In addition, it is a systemic disorder; persistent systemic inflammation may lead to 
extra-articular manifestations, and also to increased cardiovascular morbidity and 
mortality.2
The socio-economic impact is also significant. A study in 1989 demonstrated that, 
10 years after diagnosis of RA, only half of patients were employed and 42% of patients 
considered themselves disabled.3 Since then, improved understanding of the disease has 
shaped clinical practice, with the current approach to treatment being based principally 
upon the paradigm that the level of inflammation over time determines damage. Studies 
have demonstrated that damage occurs early in the disease process, and that subclinical 
inflammation and associated joint damage can continue despite improvement in patients’ 
symptoms with treatment.4 Hence, the aim of treatment of RA has advanced from symptom 
control to early and optimal control of inflammation, with use of immunosuppressive 
disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX). Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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  Comparison of treatment strategies in early RA has confirmed 
that tight control of inflammatory disease activity offers 
improved outcomes for patients. The TICORA study compared 
routine treatment (DMARD treatment and three-monthly 
assessment) to intensive management involving monthly 
assessment and escalation of DMARD treatment in the pres-
ence of even low-level disease activity, according to a protocol.5 
A similar comparison of three-monthly versus monthly assess-
ment was employed in the CAMERA study, in which treatment 
with MTX was increased, or another DMARD was added as 
necessary to meet targets of disease control.6
For a number of patients however, MTX and other 
conventional DMARDs are ineffective at achieving sup-
pression of disease activity and preventing permanent joint 
damage. This need for alternative, superior treatment options 
has led to the development of biologic therapies,   targeted 
against cells and cytokines known to play a role in the 
pathogenesis of RA (Figure 1).7 In clinical practice,   biologic 
therapies are licensed for use in patients with moderate to 
severely active RA who have not responded to DMARDs. 
This article reviews the evidence supporting their use in these 
circumstances and the emerging evidence for use outside this 
remit in patients with early RA who may not have previously 
received DMARD treatment.
Assessing efficacy of biologics
International standards for assessment of disease activity 
in RA allow comparison of response to treatment across 
studies (Table 1). When a number of outcome measures 
of disease activity were assessed using expert opinion and 
analysis of placebo-controlled trial data, 20% improvement 
in the American College of Rheumatology response criteria 
(ACR20) proved reliable at discriminating active treatments 
from placebo effects.8 This is commonly used as the primary 
outcome measure in randomized controlled trials of RA treat-
ment, including many of the trials discussed in this review. 
However, it is of no use for measuring the status of disease 
activity in the individual patient in clinic, unlike the Disease 
Activity Score (DAS), a continuous variable that relates to 
disease state and is useful in clinical practice.
TNF inhibition
The first inhibitor of the cytokine tumor necrosis factor-α 
(TNF-α), infliximab, was launched over 10 years ago, ini-
tially for use in Crohn’s disease. Since then, infliximab and 
others have been approved for use in rheumatoid disease. 
  Infliximab, adalimumab, and etanercept are blockers of TNF 
that have been used in clinical practice for several years, while 
certolizumab and golimumab have recently been developed 
and approved (Table 2). Clinical trials demonstrating their 
efficacy are discussed below.
Infliximab
An initial dose-ranging study of infliximab   demonstrated 
reduced immunogenicity and better efficacy when admin-
istered with MTX,30 and it was licensed for use with 
Cell surface proteins on 
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T lymphocytes 
(CTLA 4) 
B lymphocytes 
(CD20)
Tumor necrosis factor-α Interleukin-6
Tocilizumab Infliximab 
Adalimumab
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Figure 1 Targets of current biological therapies for RA.
Note: *Developed and assessed in clinical trials, but not yet widely available.
Abbreviations: CTLA 4, cytotoxic T-lymphocyte antigen 4; CD, cluster of differentiation.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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MTX in 1999. The ATTRACT study went on to assess 
the efficacy of infliximab with MTX in patients who had 
active RA despite at least three months of treatment with 
MTX.11 Patients were randomized to placebo or one of 
four treatment regimens: infliximab 3 mg/kg every 4 or 
8 weeks and 10 mg/kg every 4 or 8 weeks. Disease dura-
tion ranged between 0.5 and 49.9 years, but was matched 
across treatment groups, with the median duration being 
7.2–9.0 years across the groups. At 30 weeks, superior 
clinical response, assessed by the proportion of patients 
achieving ACR20 and ACR50, was seen in all groups 
receiving infliximab compared to placebo (Table 3). The 
study was continued to 54 weeks. Response with infliximab 
plus MTX was sustained, and superiority to placebo plus 
MTX remained significant.12 As efficacy was comparable 
between infliximab groups but side-effects were more 
frequent with higher doses, 3 mg/kg was chosen as the 
licensed dose. After this year, treatment was unblinded 
and patients could continue their allocated treatment over 
a further one year.31 Lower numbers of patients in the 
  placebo group (28 compared to 55–64 in the infliximab plus 
MTX groups) may be accounted for by their high rate of 
withdrawal due to lack of efficacy in the first year (36%). 
Again, clinical response was maintained, as illustrated by 
similar ACR20, ACR50 and ACR70 responses.
Progression in joint damage at one year was compared 
between groups using the mean change in the total   modified 
Sharp score from baseline. The mean change in total score 
in the MTX controls was 7.0, compared to a mean change 
ranging from -0.7 to 1.6 in infliximab-treated groups 
(P , 0.001), with the mean improvement of 0.7 seen in 
patients receiving the highest dose of infliximab.12 Even in 
patients who did not clinically respond to treatment (ie, did 
not meet ACR20 criteria), infliximab had a beneficial effect 
on radiographic progression; mean change in total score in the 
MTX nonresponders was 7.2 compared to a mean of 0.2–2.6 
in infliximab nonresponders (P # 0.002). In a   sub-analysis 
of patients with early disease (less than three years disease 
duration), even greater differences were seen with the addi-
tion of infliximab.32 Mean changes in total score were 9.1 
in MTX controls compared to -1.1 to 0.6 with infliximab 
and MTX.
Table 1 Outcome measures used in intervention studies in RA
Outcome measure Method of assessment
Composite measures of disease activity:
American College of Rheumatology (ACR) response 
criteria:
A 20%, 50% or 70% improvement in the following measures 
of disease:
  • ACR20  •  number of tender joints
 •  ACR50  •  number of swollen joints
  • ACR70  •    at least three out five further criteria: patient’s assessment of pain, global health, or 
physical function; physician assessment of global health or a laboratory marker of 
inflammation (CRP or ESR).8
Disease activity score (DAS) Calculated using a mathematical formula comprising:
 •  number of swollen joints (out of 28 specified joints in the case of DAS28)
 •  number of tender joints (out of 28)
 •  patient self-assessment of global health (on a visual analog scale)
 •  laboratory markers (CRP or eSR)
A DAS28 score of 5.1 or more is classed as high disease activity; low disease activity is 
3.2 or less, and clinical remission is less than 2.6.
Patient outcomes:
Health-related quality of life, 
Short form-36 (SF-36)
A self-assessment questionnaire measuring eight aspects of mental and physical well-being, 
summarized in the mental component summary (MCS) and physical component summary 
(PCS), judged on a scale of 0 to 100, where 0 is the worst and 100 is the best outcome.
The minimal improvement which is accepted as meaningful is a decrease of at least  
3 units.9
Health assessment questionnaire disability index 
(HAQ-Di)
A self-assessment questionnaire of 8 aspects of physical disability, giving a score of 0 to 3, 
where 0 is no disability and 3 is completely disabled.
The minimal improvement which is accepted as meaningful is a decrease of 0.22 or more.9
Radiological outcomes:
Sharp score 
(and modifications of it)
Grading of the radiographic appearance of joints according to the degree of narrowing 
of the joint space and the severity of bone erosions.10
Abbreviations: CRP, C-reactive protein; eSR, erythrocyte sedimentation rate.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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The ASPIRE study similarly compared MTX alone to 
combination with infliximab, but included only patients 
with RA of less than three years duration who were MTX-
naÏve.13 The majority of patients had not had prior exposure 
to any DMARDs. As expected, compared to the ATTRACT 
study of MTX-resistant patients, higher ACR response rates 
were seen across all treatment groups (Table 3). Despite 
the higher response rates in this study with MTX alone, 
significantly higher proportions of patients on infliximab 
in combination with MTX achieved the superior response 
levels (ACR50 and ACR70). The addition of infliximab also 
significantly decreased the progression of joint damage, 
assessed using the modified Sharp score; from the median 
increase of 0.4 with MTX alone to a median change of 0.0 
seen in infliximab treatment groups (P , 0.001).
The BeSt study compared four treatment strategies in early 
RA: MTX alone, changing to alternative DMARDs if response 
inadequate; MTX alone, adding other DMARDs in combination 
if response inadequate; combination DMARD therapy initially 
with high-dose corticosteroids; and MTX with the biologic 
agent infliximab initially.14 More rapid clinical improvement 
was achieved when a combination of DMARDs or MTX 
with infliximab was used as a first line, with less progression 
of joint damage seen on radiographs. In cases where disease 
remained effectively suppressed, drug therapies (preferentially 
corticosteroids or infliximab in the first instance) were tapered 
and withdrawn. This was most successful in the group initially 
treated with infliximab combination therapy; 53% of patients 
were on just one drug for disease control at the end of the two-
year study (compared to 31%–36% in other groups).14
Table 2 TNF inhibitors used in RA
TNF inhibitor Molecular structure Administration Randomized controlled 
trials (double-blind, 
unless otherwise stated)
• Dose 
• Route 
• Frequency
Infliximab Chimeric monoclonal 
antibody to TNF; human and  
mouse components.
• 3 or 5 mg/kg 
• intravenous 
•   At 0, 2, and 6 weeks 
then every 2 months
•   Concomitant MTX is 
necessary to decrease 
immunogenicity.
ATTRACT11,12 
Early RA and MTX-naïve: 
ASPiRe13 
Early RA: 
BeSt14 (single-blind)
Adalimumab Fully human monoclonal antibody to TNF. • 40 mg 
• Subcutaneous 
• every 2 weeks
ARMADA15 
van der Putte et al16 
Early RA and MTX-naïve: 
PReMieR17 
PROwD18
etanercept Fusion protein of the soluble TNF receptor,  
linked to the constant fragment (Fc) of 
immunoglobulin.
• 50 mg 
• Subcutaneous 
•   every week  
(or 25 mg 
twice weekly)
weinblatt et al19 
Moreland et al20 
TeMPO21 
Early RA and MTX-naïve: 
COMeT22 
Bathon et al23
Certolizumab Antigen-binding fragment (Fab) of human  
anti-TNF antibody bound to polyethylene  
glycol, as opposed to the Fc fragment present  
in other monoclonal antibodies and anti-TNF  
drugs. Developed with lack of the Fc fragment,  
with the intention of increasing its half-life and  
reducing immunogenicity.
• 400 mg 
• Subcutaneous 
•   At 0, 2, and 4 weeks 
then every 4 weeks  
(or 200 mg every  
2 weeks)
RAPiD 124 
RAPiD 225 
FAST4wARD26
Golimumab Fully human monoclonal 
antibody to TNF.
• 50 mg 
• Subcutaneous 
• every 4 weeks
GO-FORwARD27 
Early RA and MTX-naïve: 
GO-BeFORe28 
Previous Anti-TNF 
Treatment: 
GO-AFTeR29Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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Quinn et al attempted to induce clinical remission in 
very early RA (DMARD-naïve patients with less than one 
year of symptoms) in a small number of patients with poor 
  prognostic features of disease such as positive rheumatoid 
factor.33 Twenty patients were treated with MTX and ran-
domly assigned to receive either placebo or infliximab for 
one year. The primary outcome of the study was achieved 
(a difference between the groups in reduction of synovitis 
on magnetic resonance imaging at 14 weeks). Improvement 
in disease control, assessed by DAS28, was more rapid 
in the infliximab group; at 14 weeks, median DAS28 was 
  significantly lower compared with the placebo group. But 
at 2 years (one year after stopping infliximab), although 
median DAS28 was lower in infliximab-treated patients and 
within the remission range, there was no significant differ-
ence compared to placebo. There was a significant   difference 
between the groups at 2 years however: in physical function, 
assessed by the Health Assessment Questionnaire (HAQ) 
score (P , 0.05). The authors postulate that this may be due 
to the faster control of disease activity, that rapid   disease 
control may have socioeconomic benefits, and prevent 
adverse illness behavior later in the disease. Follow-up data 
suggests that early biologic treatment in patients with poor 
prognostic features may have consequences for long-term 
disease control; at 8 years, 40% of the patients initially 
treated with infliximab were still in remission, compared to 
0% of controls.34
Adalimumab
Results of the ARMADA trial were published in 2003, 
  showing the efficacy of adalimumab in combination with 
MTX.15 Similar to the ATTRACT study for infliximab, 
patients had a range of disease duration (on average 
approximately 12 years) and had active disease despite at 
least 6 months of MTX treatment. At 24 weeks, at a dose 
of 40 mg every two weeks (the dose used in current clinical 
practice), patients had significantly greater clinical responses 
at ACR20, ACR50, and ACR 70 levels (Table 4). Patients 
reported greater improvement in physical   function as 
assessed by the 0–3 scale of the HAQ score; mean improve-
ment of 0.62 with adalimumab and MTX, compared to 0.27 
with MTX alone (P , 0.001). Long-term efficacy data is 
available after a 4-year open-label extension study in which 
all patients received adalimumab in combination with MTX.35 
The proportion of patients still receiving adalimumab at 
4 years was 62%; adalimumab was stopped in 8% of patients 
due to lack of efficacy. Comparison between data at 6 months 
and 4 years, for patients in the original adalimumab treatment 
groups who continued on treatment, showed that clinical 
response with adalimumab treatment was maintained.
Keystone et al assessed the effect of adalimumab 
plus MTX on radiographic progression over one year in 
a   randomized controlled trial of MTX nonresponders.36 
Patients treated with adalimumab and MTX had a smaller 
mean change in modified total Sharp score compared to 
patients on MTX and placebo (0.1 vs 2.7; P , 0.001).
Unlike infliximab, adalimumab has been shown to be safe 
and effective when used as monotherapy. This was confirmed 
by van der Putte et al in patients who had, on average, a dis-
ease duration of 11 years, and had failed previous DMARD 
treatment (the majority of patients had failed at least three 
different DMARDs).16 The proportion of patients achieving 
an ACR20 response was significantly higher in the adali-
mumab group compared to the placebo group (46% vs 19%; 
Table 3 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of 
Rheumatology) response criteria with combination infliximab and methotrexate compared to methotrexate alone
ATTRACT11,12 ASPIRE13
MTX + 
placebo 
n = 88
MTX + INF  
3 mg/kg 
8 wkly 
n = 86
MTX + INF  
3 mg/kg  
4 wkly 
n = 86
MTX + INF  
10 mg/kg  
8 wkly 
n = 87
MTX + INF  
10 mg/kg 
4 wkly 
n = 81
MTX +  
placebo 
n = 298
MTX + INF 
3 mg/kg 
8 wkly 
n = 373
MTX + INF 
6 mg/kg  
8 wkly 
n = 378
At 30 wks (%):
  ACR 20 20 50a 53a 52a 58a
  ACR 50 5 27a 29a 31a 26a
  ACR 70 0 8 11 18a 11
At 54 wks (%):
  ACR 20 17 42a 48a 59a 59a 54 62 66
  ACR 50 8 21 34a 39a 38a 32 46a 50a
  ACR 70 2 10 17 25a 19a 21 33 37a
Note: aP , 0.001 compared to placebo.
Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate; INF, infliximab.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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P , 0.001). This has importance for patients who are unable 
to take MTX, either because of intolerance to its side-effects 
or due to a contraindication. However, as superior efficacy is 
achieved with combination treatment, MTX should be used 
when possible.
The PREMIER study investigated patients with early RA 
(disease duration up to 3 years) and poor prognostic disease 
(rheumatoid factor positive or at least 1 joint erosion).17 Patients 
were excluded if they had received specified DMARDs includ-
ing MTX. Patients were randomized to receive adalimumab in 
combination with MTX, adalimumab monotherapy, or MTX 
monotherapy. Of patients in the combination therapy arm, 62% 
achieved the primary endpoint of an ACR50 response, which 
was significantly greater in comparison to adalimumab mono-
therapy (46%) and MTX monotherapy (41%) (P , 0.001 for 
both comparisons). The rate of remission (DAS28 , 2.6) at 2 
years was 49% in patients on combination therapy, twice that 
seen in the other treatment arms. At 2 years, the mean change 
in modified total Sharp score with the combination treatment 
was 1.9 compared to 10.4 with MTX alone (P , 0.001); and 
HAQ Disability Index (DI) improved by the minimal clinically 
meaningful difference in 72% of patients on combination 
therapy compared to 58% and 63% in adalimumab and MTX 
monotherapy groups respectively (P , 0.05). Further analysis 
to determine the relationship between radiographic progression 
and clinical response demonstrated that significantly less radio-
graphic progression was achieved in patients on combination 
therapy compared to MTX monotherapy across all clinical out-
comes, including patients who showed poor clinical response 
(patients not meeting the ACR20 response criteria).37
In a sub-analysis of patients in the PREMIER study, 
effect on quality of life was assessed, using the SF-36 health 
survey, and compared to a sample of the general United States 
population (from a national survey in 1998).38 As expected, 
baseline scores for the physical component summary (PCS) 
and mental component summary (MCS) were higher in the 
US population compared to the RA group. At 2 years, the 
PCS for those receiving combination therapy increased to a 
level similar to that of the general population (47.8 vs 49.4; 
P = 0.08). For those receiving MTX monotherapy, the score 
increased but remained significantly lower than the general 
population (44.4 vs 49.4; P , 0.0001). This is impressive, 
considering that these were patients selected on the basis of 
indicators of poor prognosis.
In the PROWD study, MTX-naïve patients with early 
RA (duration up to 2 years) who had self-reported work 
  impairment were randomized to adalimumab and MTX, or 
placebo and MTX.18 There was no difference in the primary 
outcome (job loss from any cause and/or imminent job 
loss after week 16): 16% of patients on adalimumab and 
MTX compared to 27% of patients on MTX monotherapy 
(P = 0.092). There was a statistical difference however, if 
numbers over the full 56-week study period were taken: 
19% compared to 40% respectively (P = 0.005). The authors 
point out that this may be due to the fact that more patients 
in the placebo group dropped out after week 16 (25 patients) 
  compared to the adalimumab-treated group (15 patients).
etanercept
Two randomized controlled trials published in 1999 showed 
the efficacy of etanercept. One study demonstrated the 
efficacy of etanercept in combination with MTX,19 and 
the other etanercept monotherapy.20 ACR20 was achieved 
in 71% of patients on etanercept and MTX combination 
therapy compared to 27% of controls (P , 0.001), and in 
59% on etanercept monotherapy compared to 11% of con-
trols (P , 0.001) (Table 5). Study subjects were similar: 
mean disease durations were 13 years and 12 years respec-
tively, and both studies required nonresponse to previous 
DMARDs (MTX in the study by Weinblatt et al and one out 
of four specified DMARDs, including MTX, in the study by 
  Moreland et al).19,20
The TEMPO trial went on to compare three treatment 
groups in a double-blind controlled design: etanercept and 
MTX in combination, etanercept monotherapy, and MTX 
monotherapy.21 Patients also had established RA, but mean 
disease duration was lower (6.8 years), and they were required 
to have had lack of response to DMARD therapy but not 
Table 4 The proportion of RA patients achieving the levels of 
clinical improvement defined by the ACR (American College of 
Rheumatology) response criteria with combination adalimumab 
and methotrexate (ARMADA)15 and adalimumab monotherapy 
(van der Putte)16
ARMADA15 van der Putte et al16
MTX +  
placebo 
n = 67
MTX +  
adalimumab 
40 mg  
2 weekly 
n = 62
Placebo  
n = 113
Adalimumab 
40 mg 
2 weekly 
n = 110
At 24–26 wks  
(%):
  ACR 20 15 67a 19 46a
  ACR 50 8 55a 8 22
  ACR 70 5 27a 2 12
Note: aP , 0.001 compared to placebo.
Abbreviations:  ACR20,  ACR50,  ACR70,  American  College  of  Rheumatology 
response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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MTX. This explains the higher response rates seen in the 
MTX group. In this patient cohort, a significantly   better 
clinical response rate over MTX monotherapy was seen 
with etanercept and MTX at ACR50 and ACR70 levels, but 
no significant difference was seen with etanercept mono-
therapy (Table 5). However, radiographic progression was 
significantly less; at 1 year the mean change in total Sharp 
score for etanercept in combination with MTX, etanercept 
monotherapy, and MTX monotherapy was -0.54, 0.52, and 
2.80 respectively (P , 0.0001 for combination therapy vs 
MTX, and P = 0.0469 for etanercept monotherapy vs MTX). 
Improvement in patients’ self-reported physical functioning, 
HAQ DI, was significantly greater in the combination group, 
but was not significantly different between etanercept mono-
therapy and MTX monotherapy (improvements of 1.0, 0.7, 
and 0.65 respectively). Quality of life was assessed using the 
European Quality of Life Health Status Visual Analog Scale, 
and superior improvements in quality of life were reported 
by patients on combination treatment.39
Etanercept treatment was also assessed in MTX-naïve 
patients with early RA: the COMET study and a study by 
Bathon et al.22,23 COMET assessed etanercept in combination 
with MTX, and Bathon et al assessed etanercept monother-
apy. COMET was different to previous trials in early arthritis, 
as remission was used for the first time as the study endpoint 
(DAS28 , 2.6), as opposed to using ACR response criteria. 
At one year, the proportion of patients who achieved DAS28 
remission was greater with etanercept and MTX than with 
MTX alone (50% compared to 28%; P , 0.0001). This bene-
fit was sustained at 2 years; 57% of patients who continued on 
combination therapy achieved DAS28 remission, compared 
to 35% of patients remaining on MTX (P = 0.002).40 This 
remission rate is greater than that seen in studies of MTX-
naïve patients with longer disease duration, such as the 
TEMPO trial, in which the DAS28 remission rate was 42% 
at 2 years with combination treatment. Bathon et al showed 
etanercept monotherapy was more effective than MTX in the 
first 6 months, with greater percentages of patients achieving 
ACR20, ACR50 and ACR70 (P , 0.05). At 2 years, there was 
a significant difference in the proportion of patients achieving 
ACR20 (72% vs 59% of MTX controls; P = 0.005), but no 
significant difference at ACR50 and ACR70 levels.41 Patients 
completing the study by Bathon et al entered an open-label 
extension study of etanercept monotherapy, extending treat-
ment to 5 years.42 Efficacy was maintained for patients who 
remained on etanercept from the original treatment group, 
with 68% fulfilling ACR20 criteria at 5 years.
Both studies also assessed radiographic progression. In 
the COMET study, no progression (defined as a change in 
modified total Sharp score of 0.5 or less) was seen in 80% of 
patients on etanercept and MTX, compared to 59% on MTX 
alone (P , 0.0001). Similarly, nonprogression at 2 years was 
demonstrated more frequently with etanercept monotherapy 
than with MTX by Bathon et al (63% compared to 51%; 
P = 0.017). In terms of patient outcomes, COMET showed 
a significant difference in improvement in HAQ DI score 
over 1 year between patients receiving etanercept with MTX 
and MTX alone (improvements of 1.0 and 0.7 respectively; 
P , 0.001). Patients receiving etanercept and MTX also 
experienced benefits in terms of work stability; of patients 
in full or part-time work at baseline, 9% had stopped work 
at least once during the study, compared to 24% on MTX 
Table 5 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of 
Rheumatology) response criteria with combination etanercept and methotrexate and etanercept monotherapy
Weinblatt et al19 Moreland et al20 TEMPO21
MTX + 
placebo 
n = 30
MTX + 
etanercept 
25 mg  
twice weekly 
n = 59
Placebo 
n = 80
Etanercept  
25 mg 
twice weekly  
n = 78
MTX + 
placebo 
n = 228
Etanercept 
25 mg 
twice weekly 
n = 223
MTX + 
etanercept 
25 mg 
twice weekly 
n = 231
At 24–26 wks (%):
  ACR 20 27 71a 11 59a
  ACR 50 3 39a 5 40a
  ACR 70 0 15 1 15
At 52 wks (%):
  ACR 20 75 76 85
  ACR 50 43 48 69a
  ACR 70 19 24 43a
Note: aP , 0.001 compared to placebo.
Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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alone. Bathon et al also showed a difference in improvement 
in HAQ DI after 2 years; 55% of etanercept patients had 
improved by at least 0.5 units, compared to 37% of MTX 
patients (P , 0.001).
Certolizumab pegol
Results showing efficacy in rheumatoid arthritis have been 
reported in patients with RA resistant to 6 months of MTX 
(RAPID 1 and 2),24,25 and patients with RA resistant to 
6 months of MTX or other DMARDs (FAST4WARD).26 
Approximately 80% of patients in the FAST4WARD study 
had previously been treated with MTX and, on average, had 
failed two DMARDs. RAPID 1 and 2 showed efficacy of 
two different preparations of certolizumab (lyophized and 
liquid) in combination with MTX, whereas FAST4WARD 
used certolizumab as monotherapy. Success in achieving 
clinical response compared to placebo is shown in Table 6. 
RAPID 1 and RAPID 2 produced similar response rates 
with the different preparations. Therefore, only data from 
RAPID 1 is presented here, for simplicity. Clinical responses 
were maintained to week 52 in RAPID 1 and 2.
Improvement in physical function was significantly 
greater with certolizumab used in combination with MTX, 
and as monotherapy, compared to control groups. Mean 
improvement in HAQ DI was 0.6 at 52 weeks with com-
bination therapy in RAPID 1, and 0.36 at 24 weeks with 
monotherapy in FAST4WARD (P , 0.001 against placebo 
in both studies). With combination therapy in RAPID 1, 
inhibition of radiographic progression was significantly 
greater than MTX alone (P , 0.001), but was not assessed 
in FAST4WARD.
Golimumab
Efficacy in combination with MTX and as monotherapy 
has been assessed in patients who are MTX-naïve 
  (GO-BEFORE),28 and patients with active RA despite MTX 
  treatment (GO-FORWARD).27 Results in terms of ACR 
response are shown in Table 7.
Golimumab is unique amongst the anti-TNF therapies 
in that there is randomized controlled trial evidence for its 
efficacy in patients who have previously received anti-TNF 
therapy. In the GO-AFTER study, 58% of patients had 
received previous anti-TNF treatment that was stopped due 
to lack of efficacy, and 34% of patients had received more 
than one anti-TNF in the past.29 Golimumab was given with 
or without at least one DMARD. Approximately two thirds 
of patients were taking concomitant MTX. A statistically 
significant difference was seen compared to placebo in the 
percentage of patients achieving ACR20 (34% vs 17%) and 
ACR50 responses (18% vs 5%) (P , 0.001 for both levels 
of response). There was also a difference in improvement in 
HAQ DI; mean improvement was 0.3 with golimumab, but 
0.0 in controls (P , 0.001).
inhibition of T cell activation: abatacept
For T cell activation, in addition to binding to antigen, a co-
stimulatory signal is also necessary. This is produced by the 
binding of CD28 molecules on the T cell surface to CD80/
CD86 molecules on the surface of an   antigen-presenting cell. 
T cells are capable of expressing cytotoxic T-lymphocyte 
antigen 4 (CTLA 4), which binds to CD80/CD86 more 
readily than CD28, thereby preventing this second process 
required for T cell activation. Abatacept is a recombinant 
protein consisting of the extracellular domain of CTLA 4 
and human immunoglobulin; therefore, it   inhibits T cell 
activation.43 It is given intravenously at a dose of 10 mg/kg 
every 4 weeks.
Abatacept has been assessed in combination with 
DMARD therapy (usually MTX) in randomized   controlled 
trials of patients with established RA which is active despite 
MTX (AIM and Kremer et al),44,45 and despite   previous 
  anti-TNF treatment (ATTAIN)46. All   demonstrated higher 
Table 6 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of 
Rheumatology)  response  criteria  with  combination  certolizumab  and  methotrexate  (RAPiD  1)24  and  certolizumab  monotherapy 
(FAST4wARD)26
RAPID 124  FAST4WARD26
MTX + placebo n = 199 MTX + certolizumab 
200 mg 2 weekly n = 393
Placebo 
n = 109
Certolizumab 400 mg 
4 weekly n = 111
At 24 wks (%):
  ACR 20 14 59a 9 46a
  ACR 50 8 37a 4 23a
  ACR 70 3 21a 0 6
Note: aP , 0.001 compared to placebo.
Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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rates of clinical improvement and improvement in physical 
function with abatacept plus DMARD in comparison to 
DMARD alone (Table 8). In all three studies, significantly 
more patients in abatacept groups achieved clinically 
meaningful improvement in HAQ scores (P , 0.001). 
Abatacept has also been shown to improve health-related 
quality of life. For example, in the ATTAIN study, improve-
ment in PCS and MCS scores of the SF-36 was greater than 
improvement in the control group at levels of significance 
of P , 0.001 and P , 0.01 respectively. The AIM study 
also assessed radiographic change, showing approximately 
50% reduction in the progression of radiographic dam-
age when abatacept was added to DMARD treatment; 
median change in total Genenant-modified Sharp score 
from baseline was 0.25 with abatacept plus DMARD 
therapy, compared to 0.53 with DMARD therapy alone 
(P = 0.012).44
Patients completing these trials were eligible to receive 
10 mg/kg abatacept with DMARD in open-label extension 
studies. In all three studies, the ACR response rates achieved 
in the original abatacept groups were maintained at the end of 
the study periods, in the patients who remained on   abatacept. 
The rate of discontinuation due to lack of efficacy was 2% over 
the 1-year extension period of the AIM trial,47 11% over the 
4-year extension by Kremer et al48 and 16% over 18 months 
after the ATTAIN trial (patients who had   previously received 
anti-TNF).49 Radiographic progression in the original abatacept 
group of the AIM trial was significantly slower in the second 
year of treatment compared to the first, suggesting an increas-
ing effect of abatacept on structural damage in year 2.43
Abatacept in combination with MTX was assessed 
in MTX-naïve patients with early RA (disease duration 
up to 2 years) and poor prognostic factors (seropositve 
for   rheumatoid factor and/or anti-CCP), and presence of 
Table 7 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of 
Rheumatology)  response  criteria  with  combination  golimumab  and  methotrexate  and  golimumab  monotherapy  compared  to 
methotrexate monotherapy
GO-BEFORE28 GO-FORWARD27
MTX + 
placebo 
n = 160
Golimumab  
100 mg 
4 weekly  
n = 159
MTX + 
golimumab 
50 mg 4 weekly 
n = 159
MTX + 
placebo 
n = 133
Golimumab 
100 mg 
4 weekly 
n = 133
MTX + 
golimumab 
50 mg 4 weekly 
n = 89
At 24 wks (%):
  ACR 20 49 52 62b 28 35 60a
  ACR 50 29 33 40b 14 20 37a
  ACR 70 5 11b 20a
Notes: aP , 0.001 compared to placebo group; bP , 0.05 compared to placebo group.
Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; MTX, methotrexate.
Table 8 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of 
Rheumatology) response criteria with combination abatacept and methotrexate or alternative DMARD compared to DMARD alone
AIM44 Kremer et al45 ATTAIN46
MTX + 
placebo 
n = 219
MTX + abatacept 
10 mg/kg  
4 weekly  
n = 433
MTX + 
placebo 
n = 119
MTX + abatacept 
10 mg/kg  
4 weekly 
n = 115
DMARD + 
placebo 
n = 133
DMARD + 
abatacept 
10 mg/kg 
4 weekly  
n = 258
At 6 months (%):
  ACR 20 20 50a
  ACR 50 4 20a
  ACR 70 2 10
At 12 months (%):
  ACR 20 40 73a 36 63a
  ACR 50 18 48a 20 42a
  ACR 70 6 29a 8 21
Note: aP , 0.001 compared to placebo group.
Abbreviations:  ACR20,  ACR50,  ACR70,  American  College  of  Rheumatology  response  criteria  improvements  of  20%,  50%,  and  70%;  DMARD,  disease-modifying 
antirheumatic drug; MTX, methotrexate.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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radiographic erosions.50 Primary endpoints were remission 
(DAS28 , 2.6) and Genant-modified total Sharp score at 
1 year. DAS28 remission was achieved in 42% of patients in 
the abatacept and MTX group, compared to 23% receiving 
MTX alone (P , 0.001). There was also a significant   slowing 
of radiographic progression (mean change in total score 0.63 
vs 1.06; P = 0.040). Results are comparable to anti-TNF in 
early RA; for example, the COMET study of etanercept. This 
is particularly impressive, considering that patients were 
selected based on the basis of poor prognostic factors (90% 
of patients were anti-CCP positive).
Unlike other biologic treatments, the efficacy of abatacept 
in undifferentiated arthritis has been assessed.51 Patients 
were anti-CCP positive with at least two swollen and ten-
der joints, and therefore highly likely to develop RA, but 
did not yet fulfil the criteria for the 1987 definition of RA 
by the   American College of Rheumatology.52 They were 
  randomized to abatacept or placebo treatment for 6 months. 
At one year (6 months after treatment was discontinued), 46% 
of abatacept-treated versus 67% of placebo-treated patients 
developed RA (95% confidence interval for the difference 
between the groups: -47% to 7%). Abatacept also prevented 
radiographic progression; mean change in Genant-modified 
Sharp score, from baseline to one year, was 0.01 in abatacept-
treated patients vs 1.11 in placebo controls (95% confidence 
interval for difference between the groups: -2.05 to -0.15).
B cell inhibition: rituximab
Rituximab is a human-mouse chimeric monoclonal   antibody 
that selectively depletes CD20-expressing B cells. The 
mechanism by which rituximab depletes B cells may be 
by cell-mediated or complement-dependant toxicity, or by 
promotion of apoptosis.53 It has been used to treat non-
Hodgkins lymphoma since 1997, but has since been licensed 
for use in RA in combination with MTX.54 It is administered 
in two intravenous infusions of 1g, two weeks apart, with 
intravenous glucocorticoid. Usually, a clinical response is 
seen at 16 weeks and lasts at least 6 months, after which 
treatment can be repeated. Usually, response to re-treatment 
is similar to the initial response.55 Response has been shown 
to be related to the level of B cell depletion in the blood after 
the first infusion; at 12 months, 59% of patients with com-
plete depletion of B cells (below 0.0001 × 109/liter) still had 
a moderate to good clinical response, compared to 21% of 
patients with partial depletion.56 Vital et al demonstrated that 
patients who were not clinically responding to rituximab at 
6 months had higher B cell concentrations prior to treatment 
than responders, and were less likely to achieve complete 
depletion after the first infusion.57 When these nonresponders 
were re-treated with rituximab after 6 months 72% achieved 
a clinical response.
An initial open-label phase IIa study by Edwards et al 
assessed clinical response when rituximab was used alone 
and in combination with MTX or cyclophosphamide, com-
pared to MTX alone.58 Cyclophophamide (750 mg on days 
3 and 17) was used due to prior success of rituximab in 
treatment of lymphoma in the CHOP regimen (cyclophosph-
amide, hydroxydoxorubicin, vincristine and prednisolone). 
At 24 and 48 weeks, greater numbers of patients achieved 
ACR20 responses in all rituximab groups compared to MTX 
alone, but the difference was only significant for rituximab in 
  combination with MTX (Table 9). The percentage of patients 
achieving a meaningful improvement in HAQ DI (decrease 
of $0.22 from baseline) was greatest in the rituximab-MTX 
Table 9 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of 
Rheumatology) response criteria with rituximab at the dose commonly used in clinical practice (1000 mg on day 1 and day 15)
Edwards et al58 DANCER53 REFLEX60
MTX  
n = 40
Rituximab  
n = 40
CYC + 
rituximab 
n = 41
MTX + 
rituximab 
n = 40
MTX + 
placebo 
n = 121
MTX + 
rituximab 
n = 115
MTX + 
placebo 
n = 209
MTX + 
rituximab 
n = 311
At 24 wks (%):
  ACR 20 38 65 76 73 28 54a 18 51a
  ACR 50 13 33 41 43 13 34a 5 27a
  ACR 70 5 15 15 23 5 20a 1 12a
At 48 wks (%):
  ACR 20 20 33 49 65a
  ACR 50 5 15 27 35
  ACR 70 0 10 10 15
Note: aP , 0.001 compared to placebo group.
Abbreviations: ACR20, ACR50, ACR70, American College of Rheumatology response criteria improvements of 20%, 50%, and 70%; CYC, cyclophosphamide; MTX, 
methotrexate.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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group (68% vs 39% and 43% in other rituximab groups 
and 28% in the MTX monotherapy group). Follow-up was 
  continued two years after rituximab treatment. In this time, 
a number of patients discontinued from the study due to lack 
of efficacy or relapse, and received alternative therapy or re-
treatment with rituximab. At two years, 45% of patients in 
the rituximab-MTX group had not required further treatment, 
compared to 22% in the rituximab plus cylophosphamide 
group, 10% in the rituximab monotherapy group, and 15% 
in the MTX-only group.
The DANCER trial investigated differing doses of 
rituximab with MTX, with or without glucocorticoids, in 
patients with active RA despite at least three months of 
MTX treatment.53 Beyond 4 weeks, clinical response was 
not significantly affected by glucocorticoid treatment, but 
ameliorated acute infusion reactions. Therefore, results 
were pooled according to rituximab dose. When results 
for rheumatoid factor-negative patients were analyzed (85 
out of 465 patients), rituximab showed no superior efficacy 
over placebo (48% achieved ACR20 at 24 weeks compared 
to 52% of controls), and their results were excluded from 
the main analysis (Table 9). The proportion of patients 
who had a meaningful decrease in HAQ DI ($0.22 from 
baseline) was 67% with rituximab, compared to 34% in 
controls.59
Patients enrolled in the REFLEX trial had active RA 
despite three months of MTX treatment, and had failed 
previous anti-TNF treatment, either due to lack of efficacy 
(90% of patients) or intolerance.60 Rituximab had a signifi-
cant affect on HAQ DI (mean improvement of 0.4 compared 
to 0.1 in controls; P , 0.0001), and on quality of life (mean 
improvement in PCS was 5.8 vs 0.9, and MCS was 4.7 vs 
1.3; P = 0.0002 for both scores). The effect of rituximab on 
radiographic progression was assessed by comparing Genant-
modified Sharp scores at week 24 to baseline. A trend was 
seen towards reduction of radiographic progression. However, 
results did not reach statistical significance; mean change in 
total score in the rituximab group was 0.6 compared to 1.2 in 
controls (P = 0.169).
il-6 inhibition: tocilizumab
Amongst its many roles, Il-6 is involved in differentiation 
of B cells into plasma cells, and activation of T cells.61,62 
  Tocilizumab is an antibody against the Il-6 receptor, i  nhibiting 
Il-6 binding, and is produced from human   immunoglobulin 
and mouse antibody to the human Il-6 receptor by recom-
binant DNA technology. It is administered intravenously 
every 4 weeks.
Tocilizumab was used alone and in combination with 
MTX in the CHARISMA trial, in patients with an inadequate 
response to MTX.63 The study showed the greatest number 
of patients who achieved the primary endpoint (ACR20 at 
20 weeks) were those treated with tocilizumab 8 mg/kg plus 
MTX (74% compared to 41% in the placebo plus MTX 
group; P = 0.001). This is the dose used in clinical practice. 
Response with tocilizumab 8 mg/kg monotherapy was less 
impressive (Table 10).
Further evidence of efficacy of tocilizumab in   combination 
with MTX or other DMARDs is available (Table 10). The 
OPTION study included patients with an inadequate response 
to MTX. A small number had received previous anti-TNF 
treatment (51 patients; 8%).64 The TOWARD study assessed 
the combination of tocilizumab with other conventional 
DMARDs in patients with active RA despite eight weeks of 
treatment with DMARD therapy.65 Approximately 75% of 
patients were receiving MTX as the concomitant DMARD. 
Improved quality of life was seen in tocilizumab groups in 
both studies, with statistically significant differences between 
mean improvements from baseline in MCS and PCS scores 
(P # 0.001).
Table 10 The proportion of RA patients achieving the levels of clinical improvement defined by the ACR (American College of 
Rheumatology) response criteria with tocilizumab monotherapy and in combination with methotrexate or DMARD. Tocilizumab 
groups received 8 mg/kg every 4 weeks
CHARISMA63 OPTION64 TOWARD65 RADIATE66
MTX +  
placebo 
n = 49
TCZ 
n = 52
MTX + 
TCZ 
n = 50
MTX + 
placebo 
n = 204
MTX + 
TCZ 
n = 205
DMARD + 
placebo 
n = 415
DMARD + 
TCZ 
n = 805
MTX + 
placebo 
n = 160
MTX + 
TCZ 
n = 175
20–24 wks (%):
  ACR 20 41 63 74a 26 59a 25 61a 10 50a
  ACR 50 29 41 53 11 44a 9 38a 4 29a
  ACR 70 16 16 37 2 22a 3 21a 1 12a
Note: aP , 0.001 compared to placebo.
Abbreviations:  ACR20,  ACR50,  ACR70,  American  College  of  Rheumatology  response  criteria  improvements  of  20%,  50%,  and  70%;  DMARD,  disease-modifying 
antirheumatic drugs; MTX, methotrexate; TCZ, tocilizumab.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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RADIATE was a trial in RA patients who had received 
one or more anti-TNF therapies in the previous year but 
had failed treatment due to lack of efficacy or intolerance 
(approximately half of patients had failed more than one 
  anti-TNF).66 The results are similar to those seen with 
  rituximab subsequent to failed anti-TNF in the REFLEX 
study, with half of patients achieving an ACR20 response, 
compared to 10% of patients on MTX alone.
Affect on radiographic progression was assessed in the 
SAMURAI and LITHE studies.67,68 In the SAMURAI study, 
patients with an inadequate response to DMARD therapy 
were randomized to tocilizumab monotherapy or continuing 
conventional DMARD treatment. At one year, the tocili-
zumab group showed less radiographic progression, with 
a mean change in total Sharp score of 2.3 compared to 6.1 
in the DMARD group (P , 0.01). The LITHE study was 
a double-blind randomized controlled trial of tocilizumab 
combined with MTX, compared to MTX monotherapy, in 
MTX nonresponders. Again, the tocilizumab group showed 
less progression, with mean change in total Genant-modified 
Sharp score of 1.3 compared to 3.0 (P , 0.0001).
In MTX-naïve patients, the AMBITION study compared 
efficacy of tocilizumab monotherapy to MTX.69 A signifi-
cantly higher proportion of patients receiving tocilizumab 
achieved ACR20 response at 24 weeks (70% compared to 
53%; P , 0.0001), and one third of patients achieved DAS28 
remission, compared to 12% of patients receiving MTX.
For the purpose of analyzing long-term efficacy, patients 
from these randomized controlled trials (OPTION, TOWARD, 
RADIATE, LITHE, and AMBITION) were enrolled in 
long-term extension studies, in which all patients receive 
tocilizumab for up to five years, and are currently   ongoing. 
Interim results at 2.5 years have been published, showing 
continued improvement of ACR responses over time, and 
only 3% withdrawal rate due to lack of efficacy.70
Tolerability
In trials, rates of adverse events with anti-TNF treatments, 
and discontinuation rates due to adverse events, are generally 
comparable to rates seen in control groups. For example, the 
ATTRACT study demonstrated that adverse events were as 
common in all infliximab groups as in the placebo group.11 
An adverse event was reported at least once in 80% of 
patients. However, these were well-tolerated, causing the 
discontinuation of treatment in 3%–7% of patients across 
infliximab treatment groups, which compared to 8% in the 
placebo group. Infusion reactions were more common with 
infliximab (16%–20% compared to 10% in the placebo 
group), but were usually mild and transient. In the STAR 
study (Safety Trial of Adalimumab in Rheumatoid Arthritis), 
patients were randomized to adalimumab or placebo, and 
continued on their conventional DMARDs.71 There was no 
significant difference in total adverse event rates (87% with 
adalimiumab vs 83% with placebo), and when the type of 
event was considered, a significant difference between groups 
was only seen in injection site reactions (20% vs 12%), rash 
(11% vs 6%), and back pain (5% vs 3%). The TEMPO trial 
of etanercept as monotherapy and in combination with MTX 
reported similar total adverse event rates (81% and 86% 
respectively, compared to 81% with MTX monotherapy).21 In 
terms of type of event, a significant increased incidence with 
etanercept was only seen in injection site reactions.
Certolizumab and golimumab have been shown to dif-
fer from other anti-TNF therapies in that rate of injection 
site reactions are not increased compared to controls. In 
the FAST4WARD study, the rate of injection site reactions 
was 5% with certolizumab compared to 14% with placebo.26 
In GO-FORWARD the rate was 2% with golimumab com-
pared to 3% in controls.27
Trials have shown tolerability of abatacept is similar to 
anti-TNF treatment in RA. For example, the total adverse 
event rates in the AIM study were 87% with abatacept 
  compared to 84% with placebo.44 The longest running 
  open-label extension trial of abatacept treatment, by Kremer 
et al reported a 17% discontinuation rate due to adverse 
events over 5 years.48
With rituximab, the most frequent adverse events are 
infusion reactions. These are reduced by premedication 
with intravenous glucocorticoid, but remain common with the 
first infusion of each course; acute infusion reaction occurred 
in 29% of patients treated with two doses of 1000 mg 
  rituximab in the DANCER study, and 23% of patients in the 
REFLEX study.53,60 The rate decreases for the second infu-
sion (approximately 10%). Total adverse events occurred in 
85% of patients receiving two doses of 1000 mg rituximab 
in both DANCER and REFEX trials (compared to rates of 
70% and 88% in placebo groups). They were largely well-
tolerated; adverse events led to withdrawal of treatment in 
3% of patients in both trials.
In the largest randomized controlled trial of tocilizumab 
(the TOWARD study of 1,220 patients), the incidence of 
adverse events was higher in the tocilizumab group compared 
to controls (73% compared to 61%). The majority of events 
though were mild to moderate in severity and generally 
  tolerated; the discontinuation rate due to adverse events was 
4%, compared to 2% for controls.65Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
113
Biologic therapy in rheumatoid disease
Safety of biologics
There are important safety issues with the use of biologic 
therapy, not least because their targets in the immune   system 
have a role in the body’s defence against infection and 
malignancy. Difficulties arise in assessing their safety, as 
any increase in rates of malignancy and infection (both of 
which are associated with RA) may reflect greater   disease 
severity and not biologic treatment. Evidence of their 
safety is available from registries of patients receiving 
biologics; for example, the British Society for Rheumatol-
ogy   Biologics Register (BSRBR). This includes a control 
group of 3,106 RA patients treated with DMARDs, but 
these patients are likely to have less severe disease if they 
have not required biologic therapy. Randomized controlled 
  trials are generally not powered to detect rare adverse effects 
such as malignancy. Meta-analyses of trials may go a way 
towards solving this issue. However, it is important to note 
that trials may exclude patients with co-morbidities, and 
therefore their results may not apply to the general RA 
population.
infection
There is an increased risk of infection with biologic 
therapy, and they are contraindicated in the presence of 
active, severe infection. Risk of serious infection (infection 
requiring intravenous antibiotics, or leading to hospitaliza-
tion or death) with biologic treatment is summarized in 
Table 11.
There is an increased risk of tuberculosis (TB), either 
reactivation of latent infection or increased susceptibil-
ity to infection. It can present atypically, for example, as 
extra-pulmonary or miliary TB. Out of the 10,403 patients 
on anti-TNF therapy in the BSRBR, there have been 
35 cases of TB, with no cases in the DMARD group.76 
There is a difference in risk within the group of anti-TNFs. 
Adalimumab and infliximab (the monoclonal antibodies) 
are associated with higher rates compared to the receptor 
fusion protein etanercept. This may be due to differences 
in their   mechanism of action. The monoclonal antibodies 
also inhibit T cell   activation and the production of inter-
feron gamma, whereas the function of interferon gamma is 
preserved with etanercept treatment.77 All patients should 
be screened for latent infection prior to receiving anti-TNF. 
The optimal treatment for latent TB prior to commencing 
anti-TNF treatment has not been investigated in trials. 
Observational data, for example, from the Spanish biologics 
registry, reports that screening for TB and treatment with 
isoniazid prior to anti-TNF therapy significantly decreases 
the risk, but does not eliminate it.78 There is no evidence 
that rituximab increases the risk of TB in clinical trials. 
Trials excluded patients with active TB or latent TB on 
chest X-ray, but have not screened for latent TB by purified 
protein derivative testing.
Anti-TNF treatments are contraindicated in chronic 
  hepatitis B infection, as infliximab has been associated with 
viral reactivation in a number of case reports.76 Etanercept is 
considered to be safe in hepatitis C. A prospective study of 
eight patients and a randomized controlled trial have shown 
no increase in viral load or adverse events with etanercept.80,81 
Hepatitis B reactivation has been reported after rituximab 
treatment in lymphoma patients, but successful treatment 
with prophylaxis has been possible. RA trials have screened 
Table 11 Risk of serious infection with biologic treatment
Biologic 
agent
Risk of serious infection
Anti-TNF A meta-analysis of trials of infliximab and 
adalimumab calculated the risk was approximately 
double that with conventional DMARD 
treatment (odds ratio 2.0; 95% confidence 
interval: 1.3 to 3.1).72
A retrospective observational study of over 700 
patients on anti-TNF compared the incidence of 
serious infections on treatment to the incidence 
in the same patients prior to treatment.73 Rates 
of serious infection in the first year were 10 per 
100 patient years compared to 3 per 100 patient 
years prior to anti-TNF treatment.
The rate of serious infection from BSRBR data 
was 6 per 100 patient years.74 when adjustment 
was made for confounding factors such as  
co-morbidities, this was not significantly different 
from the rate in patients on conventional 
DMARDs. However, when the incidence rate 
over the first 90 days of anti-TNF treatment was 
calculated, a four-fold increase in serious 
infections was seen in this initial period of 
treatment.
Abatacept in the open-label extension trials discussed 
previously, the rate of serious infections was 3–5 
per 100 patient years across the studies. 47–49
Rituximab in the DANCeR and ReFLeX trials, incidence of 
serious infection was 5 per 100 patient years in 
both trials (compared to rates of 3–4 per 100 
patient years in control groups).53,60 Long-term 
safety data with repeated treatments has shown 
similar rates of serious infection for each cycle of 
treatment.75
Tocilizumab in the TOwARD study, the rate of serious 
infection was 6 per 100 patient years, compared 
to 5 per 100 patient years with DMARD therapy 
alone.65
Abbreviation: BSRBR, British Society for Rheumatology Biologics Register.Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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for hepatitis B and C prior to treatment. Therefore, screening 
for hepatitis B and C is recommended.54
There are case reports of fungal infections with anti-
TNF therapy, for example, histoplasmosis or aspergillosis, 
although the incidence is extremely low.79
Malignancy
There is concern that anti-TNF and abatacept therapies may 
put patients at risk of malignancy due to the role of TNF and 
T cells in cancer immunosurveillance.
A meta-analysis of adalimumab and infliximab trials 
has shown increased rates of malignancy compared to 
placebo or placebo plus DMARD (pooled odds ratio 3.3; 
95%   confidence interval: 1.2 to 9.1). However, these trials 
included high doses of infliximab (6 mg/kg every eight 
weeks or more).72 Observational studies indicate that 
anti-TNF therapy is associated with an increased risk of 
nonmelanotic skin cancers but not solid tumor malignan-
cies. For example, a study of approximately 3,000 patients 
treated with anti-TNF in the United States of America 
reported an incidence rate of nonmelanotic skin cancer of 
26 per 1,000 patient years, compared to 20 per 1,000 patient 
years in patients treated with conventional DMARDs.82 
A Swedish study reported a standardized incidence rate 
of solid tumors of 0.9 in 4,000 RA patients on anti-TNF, 
which compared to the standard incidence rate of 1.05 in 
over 50,000 RA patients.83 However, anti-TNF may have 
been avoided in patients at risk of malignancy, or with a 
previous history of malignancy, because of a theoretical 
risk. Data available from the BSRBR, of patients with a 
history of previous malignancy, does not demonstrate any 
increased cancer risk with anti-TNF.84
Anti-TNF treatment is contraindicated in patients with a 
history of a lymphoproliferative disorder within the last five 
years. There have been reports of higher incidence rates of 
lymphoma in patients on anti-TNF therapies in comparison 
to rates seen in the general RA population; for example, 
the French RATIO registry data.85 In other cohort studies 
however, such as the Swedish cohort described above, no 
increase in incidence has been seen.86
With abatacept, a total of 42 malignancies were seen in 
the 1,167 patients who were exposed to at least one dose 
of abatacept in the open-label extension studies discussed 
previously.47–49 The commonest types were nonmelanotic skin 
cancers (21 cases), pulmonary malignancy (6 cases), and 
lymphoma (3 cases). This incidence of pulmonary neoplasm 
and lymphoma is similar to that in the RA population.
Anaphylaxis
Infliximab has a higher propensity than other anti-TNF 
therapies to cause anaphylaxis, as it is a chimeric molecule, 
but maybe also because it is administered intravenously. In 
the START study (Safety Trial for Rheumatoid Arthritis 
with Remicade Therapy), 5 out of 1,442 patients treated with 
infliximab developed serious infusion reactions.87
Rituximab, another chimeric molecule, is   contraindicated 
in patients who have had a hypersensitivity reaction to 
  infliximab. In the REFLEX study, only two infusion   reactions 
out of 308 rituximab-treated patients were reported as severe, 
one reaction being anaphylaxis, the other hypertension.60
Autoimmune syndromes and psoriasis
Anti-TNF therapy is associated with the production of 
autoantibodies (antinuclear antibodies and double-stranded 
DNA antibodies). Rarely, anti-TNF can cause   autoimmune 
hepatitis, vasculitis, and drug-induced systemic lupus 
  erythematosus (occurring in approximately 0.2% of 
patients).79 These conditions generally improve with drug 
withdrawal. There are also reports of new-onset of skin 
psoriasis and worsening of existing psoriasis on anti-TNF 
therapy. There have been 25 new cases of psoriasis in 
patients on anti-TNF treatment in the BSRBR, equivalent to 
an incident rate of 1.04 per 1,000 patient years, compared to 
no cases in patients on conventional DMARDs.88
Autoimmune syndromes have also been seen with 
  abatacept. The extension studies reported vasculitis in 
9 patients.47–49 Other, rarer events were sicca syndrome 
(3 patients), erythema nodosum (2 patients), multiple scle-
rosis, systemic lupus erythematosus, and sjögrens syndrome 
(1 patient each). There were 16 new cases of psoriasis.
Neurological
Anti-TNF is contraindicated in patients with a history of 
Parkinson’s disease or demyelinating conditions such as 
optic neuritis or multiple sclerosis, and treatment should be 
stopped if these disorders occur on treatment. Case reports 
of development of demyelinating disorders on anti-TNF 
therapy have been published.79 The role of anti-TNF therapy 
in their causality is impossible to prove, but is suggested by 
the fact that they generally improve, at least partially, on 
drug withdrawal.
After treatment with rituximab, the very rare but usually 
fatal condition of progressive multifocal leukoencephalopa-
thy has been seen. A review of cases from post-marketing 
surveillance and published literature up until December 2008 Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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revealed 57 cases.89 Cases were in patients with known risk 
factors for the disease, including lymphoma and treatment 
with additional potent immunosupressants. This included one 
patient with RA who had previously received chemotherapy 
for oral malignancy.
Hematological
Pancytopenia and aplastic anemia while on anti-TNF therapy 
have been reported. Again, it is difficult to conclude that this 
is caused by anti-TNF treatment, as these cases are extremely 
rare,79 but if these conditions develop, anti-TNF treatment 
should be stopped.
Neutropenia is a complication of tocilizumab treatment. 
In the TOWARD study, 29% of patients in the tocilizumab 
group had neutrophil levels below the normal range, com-
pared to 4% of patients in the control group.65 Importantly, 
neutropenia was not associated with any infection-related 
adverse events. Only 4% had severe neutropenia (neutrophils 
less than 500 per mm3).
Cardiovascular
Patients with rheumatoid arthritis have a higher incidence 
of cardiovascular disease than the general population, with 
a cardiovascular mortality rate of approximately 1.5 times 
higher than the general population.2 Raised levels of inflam-
matory markers and cytokines are associated with increased 
risk of cardiovascular disease, and research has shown levels 
of TNF are increased in congestive heart failure. On this 
basis, randomized controlled trials of etanercept in conges-
tive heart failure were conducted, but were terminated early 
due to higher mortality rates with etanercept treatment.90 
There are also reports of new-onset congestive heart fail-
ure and worsening of existing heart failure with anti-TNF 
therapy (without other identifiable risks or precipitating 
factors). Anti-TNF therapy is therefore contraindicated in 
moderate to severe heart failure (New York Heart Associa-
tion class III or IV). Rituximab is also contraindicated in 
severe heart failure (New York Heart Association class IV), 
but data is not available in patients with heart failure in 
classes I to III.70
Tocilizumab, by suppressing the effect of IL-6 on the 
liver, is associated with increased lipid levels (which are sup-
pressed by inflammation). For example, the TOWARD study 
revealed low-density lipoprotein cholesterol increased to over 
160 mg/dl in 16% of patients, compared to 3% of controls.65 
Levels improve with lipid-lowering therapy. However, the 
implication for long-term cardiovascular safety is uncertain.
Pregnancy
There is a lack of evidence for the safety of biologic therapy 
in pregnancy and lactation. There is data available for 
32 pregnancies in the BSRBR.91 Twenty three women were 
receiving anti-TNF therapy at the time of conception, and 
the majority (21 women) discontinued anti-TNF during the 
first trimester. Of these 23 pregnancies, first trimester miscar-
riage occurred in 6, elective miscarriage in 3, and out of 14 
live births there were no congenital malformations. Three of 
the women who spontaneously miscarried were also taking 
MTX, which makes this data difficult to interpret.
Discussion
Rheumatoid disease, being a chronic condition, requires 
drug treatments that are effective, well-tolerated, and safe 
over the long term. Although it is generally not   immediately 
life-threatening, it can lead to significant disability, job loss, 
and systemic complications such as cardiovascular disease. 
Benefits need to be balanced against potential risks of 
  biologic treatments.
Patients and physicians need to be aware of the risks 
with biologic treatment, which include an increased risk 
of infection (all biologics), development of autoimmunity 
(anti-TNF therapy and abatacept), and deterioration of 
heart failure (anti-TNF and possibly rituximab). Prior to 
 treatment, patients should be fully assessed for potential risks. 
  Screening for TB and hepatitis is recommended due to the 
risk of reactivation with anti-TNF. The potential increased 
risk of lymphoma with anti-TNF treatment remains unclear. 
A history of a lymphoproliferative disease within the last 
five years remains a contraindication to anti-TNF. Although 
adverse event rates with biologic treatment are high in 
  randomized studies, they are generally comparable to rates 
with conventional DMARDs. The exception to this is infu-
sion or injection site reactions. However, these are mostly 
well-tolerated and decrease over time, only infrequently 
leading to drug discontinuation.
Biologic therapies are available for patients with RA 
who are resistant to conventional DMARDs. Trials have 
  demonstrated the efficacy of biologics over conventional 
DMARDs in these circumstances, with greater proportions 
of patients achieving ACR20 responses. For example, 
one of the earliest trials, the ATTRACT study, showed 
that patients were twice as likely to achieve an ACR20 
response at one year with infliximab and MTX treatment 
compared to MTX alone.12 This holds clinical meaning for 
patients. An ACR20 is a composite endpoint that includes Drug, Healthcare and Patient Safety 2010:2 submit your manuscript | www.dovepress.com
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  improvement in the number of swollen and tender joints, 
but also the individual patient’s assessment of their pain, 
health, and physical functioning. Trials have also reported 
the proportion of patients achieving meaningful improve-
ment in physical functioning and health-related quality of 
life. This perhaps carries more meaning for patients than 
do reports of the average improvement in scores, which 
could be affected by a dramatic improvement in a small 
minority of patients. It should be noted that the majority of 
studies discussed in this review are of patients with active 
arthritis with high tender and swollen joint counts at enrol-
ment. In clinical practice, patients often have lower tender 
and swollen joint counts. Therefore, the responses seen in 
the trials discussed here may not be directly applicable to 
a number of patients.
Several anti-TNF drugs have been developed, with differ-
ent methods of administration but similar efficacy. A range of 
available anti-TNF therapies has been important for clinical 
practice, as some patients develop side-effects specific to 
certain drugs, and others may not respond or may lose their 
initial response to therapy. In the latter, there is observational 
evidence that switching to alternative anti-TNF is successful.92 
In the case of golimumab, there is evidence from a random-
ized controlled trial.29 Other classes of biologics have proved 
necessary because, in a proportion of patients, anti-TNF is 
ineffective or is contraindicated; for example, in patients 
with malignancy. Evidence for the use of the other classes 
of biologics in anti-TNF nonresponders is available from 
clinical trials of abatacept,46 rituximab,60 and tocilizumab.66 
Approximately half of patients on these treatments were 
achieving ACR20 responses at 6 months, which is striking, 
considering these were patients with disease that had been 
difficult to treat.
Efficacy of biologic treatments has been assessed in 
patients recently diagnosed with RA who have not yet 
failed conventional treatments such as MTX.13,17,23,33,50,69 
These studies have shown that a greater proportion of 
patients achieve the higher levels of improvement (ACR50 
and ACR70 responses), and higher rates of clinical remis-
sion, with biologics compared to conventional DMARDs. 
For example, the COMET study showed that patients were 
nearly twice as likely to achieve remission with etanercept 
and MTX compared to MTX alone after one year (remis-
sion rates of 50% compared to 28%).22 Improved rates of 
remission in the early stages of disease may have important 
consequences for the future in these individuals. For instance, 
as onset of rheumatoid disease occurs most commonly in 
middle age, any disruption of a person’s ability to work at 
this stage could have implications for their later career. It 
may also be important in preventing early joint damage, 
which is more rapid in the early stages of the disease, and 
so limit future disability from structural deformities. Both 
of these aspects of efficacy of early biologic treatment have 
been demonstrated; for example, reduction in job loss (in the 
PROWD study)18 and prevention of structural damage (in the 
COMET study).22
It has been suggested that early biologic treatment 
may arrest the disease if used early in its course, and that 
long-term remission after cessation of biologic treatment 
may be   achievable. For example, drug withdrawal was 
most   successful in the infliximab arm of the BeSt study;14 
  sustained remission one year after withdrawal of infliximab 
was achieved by Quinn et al in very early RA;33 and   reduction 
in rate of progression of undifferentiated arthritis to RA has 
been seen six months after withdrawal of abatacept.52 As 
discussed above, biologic therapies are not without any safety 
concerns and are financially costly. Therefore, it has been 
proposed that if biologic therapies were available as first-line 
treatments in clinical practice, patients should be selected, 
perhaps by predictors of poor prognosis.93 Initial financial 
cost may be offset if biologic therapy enables more young 
people to stay in work, reducing long-term healthcare costs 
by preventing later disability and other consequences of RA 
such as cardiovascular disease, and especially if drug-free 
remission can be attained.
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